These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 30169635

  • 41. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L.
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [Abstract] [Full Text] [Related]

  • 42. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
    Ohya Y, Makihara N, Wakisaka K, Morita T, Ago T, Kitazono T, Takaba H.
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):e128-e131. PubMed ID: 29555397
    [Abstract] [Full Text] [Related]

  • 43. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [Abstract] [Full Text] [Related]

  • 44. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
    Vlacho B, Giner-Soriano M, Zabaleta-Del-Olmo E, Roso-Llorach A, García-Sangenís A, Morros-Pedrós R.
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
    [Abstract] [Full Text] [Related]

  • 45. Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban.
    Nishino M, Okamoto N, Tanaka A, Mori N, Hara M, Yano M, Makino N, Egami Y, Shutta R, Tanouchi J.
    J Cardiol; 2016 Aug; 68(2):156-60. PubMed ID: 26443373
    [Abstract] [Full Text] [Related]

  • 46. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
    Antoniou T, Macdonald EM, Yao Z, Hollands S, Gomes T, Tadrous M, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network.
    CMAJ; 2017 Jan 09; 189(1):E4-E10. PubMed ID: 28246253
    [Abstract] [Full Text] [Related]

  • 47. [Dabigatran specific antidote: new safety level in oral anticoagulation].
    MMW Fortschr Med; 2015 Nov 05; 157(19):78-9. PubMed ID: 26953416
    [No Abstract] [Full Text] [Related]

  • 48. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
    Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener HC, Wallentin L, Yusuf S, Connolly SJ.
    Europace; 2016 Jul 05; 18(7):973-8. PubMed ID: 26944733
    [Abstract] [Full Text] [Related]

  • 49. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
    Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G.
    Europace; 2018 Feb 01; 20(2):253-262. PubMed ID: 28520924
    [Abstract] [Full Text] [Related]

  • 50. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW, Svanström H, Lund M, Pasternak B, Melbye M.
    Int J Cardiol; 2018 Oct 01; 268():113-119. PubMed ID: 29934230
    [Abstract] [Full Text] [Related]

  • 51. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N.
    Thromb Haemost; 2015 Jun 01; 113(6):1247-57. PubMed ID: 25739533
    [Abstract] [Full Text] [Related]

  • 52. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA, Chee KH, Lo YL.
    Int J Clin Pharm; 2016 Oct 01; 38(5):1182-90. PubMed ID: 27450507
    [Abstract] [Full Text] [Related]

  • 53. Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran.
    Byron M, Zochert S, Hellwig T, Gavozdea-Barna M, Gulseth MP.
    Am J Health Syst Pharm; 2017 Apr 01; 74(7):461-465. PubMed ID: 28188221
    [Abstract] [Full Text] [Related]

  • 54. Effectivity of hemodialysis in acute gastrointestinal bleeding associated with dabigatran overdose.
    Kilit C, Erarslan S, Pasali Kilit T.
    Acta Gastroenterol Belg; 2017 Apr 01; 80(2):322. PubMed ID: 29560702
    [No Abstract] [Full Text] [Related]

  • 55. Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals.
    Perram J, Joseph J, Holloway C.
    BMJ Case Rep; 2015 Nov 20; 2015():. PubMed ID: 26590187
    [Abstract] [Full Text] [Related]

  • 56. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N, Mastroiacovo D, Tamborini-Permunian E, Vitale J, Giorgi-Pierfranceschi M, Cei M, Dentali F.
    J Cardiovasc Med (Hagerstown); 2017 Jul 20; 18(7):467-477. PubMed ID: 28509761
    [Abstract] [Full Text] [Related]

  • 57. Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
    Verdecchia P, Vedovati MC, Conti S, Giustozzi M, Aita A, Molini G, Angeli F, Turturiello D, Becattini C, Cavallini C, Agnelli G.
    Expert Opin Drug Saf; 2018 Nov 20; 17(11):1063-1069. PubMed ID: 30260252
    [Abstract] [Full Text] [Related]

  • 58. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
    Stabile E, Izzo R, Rozza F, Losi MA, Coscioni E, Trimarco B.
    High Blood Press Cardiovasc Prev; 2016 Jun 20; 23(2):115-22. PubMed ID: 27207360
    [Abstract] [Full Text] [Related]

  • 59. Dabigatran-induced acute hepatitis.
    Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A.
    Clin Appl Thromb Hemost; 2012 Sep 20; 18(5):549-50. PubMed ID: 22962308
    [No Abstract] [Full Text] [Related]

  • 60. Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.
    Vene N, Mavri A, Gubenšek M, Tratar G, Vižintin Cuderman T, Pohar Perme M, Blinc A.
    PLoS One; 2016 Sep 20; 11(6):e0156943. PubMed ID: 27280704
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.